1Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J hypertens ,1996 ,14(suppl.2):S47-S54.
2刘力生.中国高血压防治指南(试行本)[Z].,1999．5..
3GU DF, Kristi R, WU XG, et al. Prevalence,awareness, treatment, and control of hypertension in China. Hypertension, 2002,40:920-927.
4Macones GA, Goldie SJ, Peipert JF. Cost-Effectiveness Analysis: An Introductory Guide for Clinicians. GME ,1999,54:663-673.
5Stewart A, Schnier JK, Luce BR, et al. A survey of standards and guidelines for cost-effectiveness analysis in health care. Am heart J, 1999,137:S53-S61.
6Johannesson M, Jonsson B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy, 1991,19:55-78.
7Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics, 1996,10:460-466.
8Mark DB, Simons TA, Durbam MA. Fundamentals of economic analysis. Am Heart J, 1999,137:S38-S40.
9Evans DB. What is cost-effectiveness analysis ? The M J of Austra,1990 ,153(suppl):S7-S9.
10Esso HD, Stamper MJ, Rosner B, et al. Systolic and diastolic blood pressure , pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension, 2000,36:801-807.
